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Abstract
	 Background: To	 assess	 antimicrobial	 susceptibility	 of	 extended-spectrum	 β-lactamase-	
(ESBL-)	 producing	 Klebsiella pneumoniae	 and	 Escherichia coli isolates	 from	 Hospital	 Tengku	
Ampuan	Afzan	(HTAA),	as	well	as	to	identify	ESBL	genes.	
 Methods: Non-duplicate	K. pneumoniae	 and	E. coli isolates	were	recovered	 from	various	
clinical	 samples.	 Isolates	 were	 screened	 for	 antimicrobial	 resistance	 by	 disc	 diffusion	 method.	




against	K. pneumoniae	and	E. coli.	ESBLs	were	detected	among	35.5%	(39/110)	of	K. pneumoniae	
and	18.8%	(28/149)	of	E. coli isolates.	CTX-M	β-lactamase	was	detected	in	90%	of	all	ESBL-positive	
isolates,	whereas	blaSHV	 and	blaTEM	 genes	were	 found	among	56%	and	52%	of	 them,	 respectively.	
Twenty-eight	 percent	 (28%)	 of	 the	 total	 ESBL-positive	 isolates	 harboured	 the	 three	 ESBL	 genes,	
while	50%	carried	two	of	the	tested	ESBL	genes.






 Over the past several decades, antibiotic-
resistant Enterobacteriaceae have increased 
significantly, being reported worldwide and 
causing a real health issue that is expensive to 
treat. Escherichia	coli and Klebsiella	pneumoniae 
in particular are the most common pathogens 
associated with drug resistance and can exhibit 
resistance to multiple antibiotics and even to 
all currently known antibiotics (1,2). These 
pathogens, whose normal habitats are the 
intestinal tract of humans and animals, are 
frequently associated with serious nosocomial 
as well as community-acquired infections such 
as pneumonia, sepsis, urinary tract infections, 
and several intra-abdominal infections (1–4). 
Genes encoding extended spectrum β-lactamases 
(ESBLs) are currently one of the most common 
drug resistance determinants (1,3). 
 ESBLs are heterogeneous enzymes 
characterised by their ability to hydrolyse almost 
all β-lactam antibiotics except carbapenems 
and cephamycins. They can be inhibited by 
β-lactamase inhibitors such as clavulanic acid 
and tazobactam (5,6). According to Bush and 
Jacoby’s (7) classification system of β-lactamase, 
most ESBLs are assigned to subgroup 2be. ESBL 
resistance genes are plasmid-encoded genes 
generated by genetic mutations and modifications 
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of native blaSHV-1 and/or blaTEM-1 genes (8,9). 
These genes are commonly found with other 
resistance genes, causing a co-resistance profile 
inclusive of other non-β-lactam antibiotics such 
as aminoglycosides and tetracycline (10). More 
than 150 different variants of ESBLs among 
Enterobacteriaceae and other genera are the 
cause of several outbreaks worldwide (5,6,11). 
ESBL was initially detected in the 1980s among K.	
pneumoniae isolates in Europe and subsequently 
spread widely elsewhere. TEM-1, TEM-2 and 
SHV-1 derivatives were the most common ESBL 
types until the 1990s and have been associated 
with several outbreaks throughout the world. 
However, since the past decade the scenario has 
changed and CTX-M-type ESBL has increasingly 
been reported and is becoming the dominant 
ESBL-encoding gene, especially among E.	 coli 
isolates (12). In this cross-sectional study, we 
evaluated the antimicrobial susceptibility pattern 
of ESBL-producing K.	 pneumoniae and E.	 coli 
bacilli isolated from patients admitted to Hospital 
Tengku Ampuan Afzan (HTAA) and determined 
the genes that were associated with ESBL 
phenotype among the isolates.
Materials and Methods
Bacterial	strains	
 Over a period from May to September, 
2014, a total of 259 non-duplicate E.	coli and K.	
pneumoniae isolates were serially included in 
this study. These isolates were recovered from 
various types of clinical specimens sent to the 
bacteriology laboratory in HTAA. HTAA is a 
tertiary hospital in Pahang and a referral for many 
district hospitals within Pahang as well as certain 
regions of southern Terengganu. The specimens 
were collected from both outpatients and 
inpatients. The isolates were derived from blood 
(n = 101), urine (n = 135), and swabs (n = 23), 
respectively. API20E (bioMerieux, France) along 
with conventional differential culture media were 
used to identify the isolates to the species level.
Antimicrobial	susceptibility	testing
 Susceptibility testing was performed for all 
the identified clinical isolates by the standard 
Kirby-Bauer disc diffusion method according to 
the Clinical and Laboratory Standards Institute 
(CLSI) guidelines (13). ATCC 25922 E.	 coli was 
used as control strain and was run simultaneously 
with the test organisms. The antibiotics used 
included: amoxicillin/clavulanic acid (20/10 μg), 
gentamycin (10 μg), amikacin (30 μg), ampicillin 
(10 μg), ciprofloxacin (5 μg), piperacillin (100 
μg), piperacillin/tazobactam (100/10 μg), 
sulbactam/ampicillin (10/10 μg), ceftazidime 
(30 μg), cefotaxime (30 µg), cefuroxime (30 
µg), cefepime (30 µg), chloramphenicol (30 
µg), trimethoroprim/sulfamethozaxole (25 
µg), imipenem (10 μg), meropenem (10 µg), 
ertapenem (10 µg), and polymyxin B (300 μg). 
All of the antibiotic discs were manufactured by 
Becton Dickinson (USA).
Phenotypic	Detection	of	ESBL
 Isolates that showed resistance to oxyimino-
cephalosporins (ceftazidime and/or cefotaxime) 
were considered as putative ESBL producers and 
were further subjected to ESBL phenotypic tests 
using combination disc diffusion as recommended 
by Clinical and Laboratory Standards Institute 
(CLSI) document M100–S21 (13). In this 
phenotypic test, discs (Becton Dickinson, USA) of 
ceftazidime (30 μg) and cefotaxime (30 µg) alone 
and with clavulanic acid (30/10 μg) were used. 
An increase of >5 mm in the zone of inhibition 
for the combination of ceftazidime or cefotaxime/
clavulanic acid disc versus the zone for the disc 
containing the drug alone was considered a 
confirmed ESBL producer. ATCC 25922 E.	 coli 
was used as non-ESBL-producing strain.
Molecular	characterization	of	ESBL
 DNA was obtained using a boiling method 
similar to that described by Mathers et al., 
(14) with some modifications. 1 mL of a fresh 
overnight bacterial broth was transferred to 1.5 
mL Eppendorf tube and centrifuged for 3 minutes 
at 8000x g. The supernatant was removed and 
the cell pellet re-suspended in 300 μL of sterile 
distilled water. The tubes were placed at 95 oC for 
20 minutes and then centrifuged at 10000x g for 
3 minutes. Finally, the supernatants were used 
as DNA template for polymerase chain reaction 
(PCR) amplification. Biophotometer (Eppendorf, 
Germany) was used to determine the purity and 
quality of extracted DNA.
PCR	amplification	and	detection
 Phenotypic ESBL-positive isolates were 
screened for SHV, TEM, CTX-M β-lactamases 
using conventional PCR amplification assay, 
based on published primer sequences by 
Wiegand et al. (15) (Table 1). PCR reactions were 
conducted using Taq polymerase (Top Taq® DNA 
polymerase, Qiagen, Germany) under conditions 
recommended by the manufacturer and 10 uL 
of the boiled bacteria was used as template. E.	
coli ATCC 25922 was used as negative control. 
PCR cycling protocols were 5 minutes at 95 °C 
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followed by 35 cycles at 94 °C for 60 s, annealing 
temperature specific for each primer (Table 1) 
for 1 minute, and extension for 7 minutes at 72 
°C. 10 μL of each PCR product was subsequently 
separated by electrophoresis in 1.5% agarose at 
100 volts for 45 minutes. A 100 base pairs (bp) 
DNA ladder was used as molecular weight marker. 
Ethidium bromide (Merck Milipore, Germany) 
was used for DNA staining and finally visualised 





 Standard identification methods using 
API 20E and conventional culturing methods 
revealed that 149 of the total isolates were E.	coli 
and 110 K.	 pneumoniae. E.	 coli was commonly 
derived from urine (30.5%), followed by blood 
(22.7%), and swabs (4.2%). A similar pattern of 
the specimens’ frequency for K.	 pneumoniae 
was observed, where 21.6%, 16.2%, and 4.6% 
were recovered from urine, blood and swabs, 
respectively. High resistance rates were found 
against ampicillin, piperacillin and trimethoprim-
sulfamethoxazole, whereas carbapenems, 
amikacin and polymyxin B were demonstrated 
to be very effective antibiotics by in vitro tests, 
showing less than 10% susceptibility rates (Table 
2). Overall, K.	pneumoniae isolates were observed 
to have higher resistance rates than E.	coli  strains. 
Less than 5% of the K.	pneumoniae isolates were 
resistant to carbapenems. Meanwhile, 100% of 
the E.	coli isolates were susceptible to merepenam 
and imipenem, and only one isolate (0.7%) was 
resistant to ertapenem. 
ESBL	detection	and	characterization
 ESBL was detected among 35.5% (39/110) 
K.	 pneumoniae and 18.8% (28/149) of E.	
coli isolates. The majority 41/67 (61.2%) 
were recovered from urine followed by 26/67 
(38.8%) from blood. Distribution of ESBL genes 
among isolates are shown in Table 3. Molecular 
characterisation revealed that 90.0% (45/50) of 
the total ESBL-producing isolates were blaCTX-
M-positive (Table 3). The	blaSHV and blaTEM genes 
were found in 56% and 52%, respectively, of the 
total ESBL-positive isolates. Twenty-eight percent 
(28%) (14/50) of the ESBL-positive strains were 
found carrying the three genes in the same isolate. 
Moreover, 50% of ESBL-positive strains carried 
two of the ESBL genes, blaCTX-M +blaSHV or blaCTX-M 
+ blaTEM combination. 
Discussion
 This is a study on antibiotic resistance and 
ESBL genotyping of K.	 pneumoniae and E.	
coli, which are nosocomially and community-
associated bacteria commonly harbouring ESBLs. 
Such study is lacking in the Eastern region of 
Malaysia. We found that carbapenems were still 
the most active antibiotics against K.	pneumoniae 
and E.	coli. Careful usage of this drug as the last-
line antibiotic to cure infection caused by EBLS-
producing Enterobacteriacea is crucial in order 
to curb incidence of carbapenem resistance. 
However, low rates of carbapenem resistance were 
detected from this study, which makes it worthy 
of further investigation in the future. Other than 
carbapenems, piperacillin/tazobactam, amikacin, 
and polymycin B also generally have high 
susceptibility rates in both species, even though 
K.	 pneumoniae showed increased resistance 
towards these drugs. A new class of antibiotic, 
glycylcycline, has been designed to reduce the 
development of antibiotic-resistant bacteria. Thus 
far, the only drug approved by the Food and Drug 
Administration under this class is tigecycline. 
Even though this drug is active against multidrug-
resistant bacteria, it has not yet been introduced 





blaCTX-M F-GCTTTGCGATGTGCAG 550 53 
R-ACCGCGATATCGTTGGT
blaTEM F-ATTCTTGAAGACGAAAGGGCCTC 1050 55 
R-TTGGTCTGACAGTTACCAATGC
blaSHV F-ATGCGTTATATTCGCCTGTG 400 54 
R-GTTAGCGTTGCCAGTGCTCG
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in HTAA due to the low rate of resistance towards 
carbapenems, amikacin and polymyxin B. 
Accordingly, no record on susceptibility testing 
against tigecycline was available. 
 ESBLs among K.	 pneumoniae and E.	 coli 
have been reported in almost every region 
throughout the world. In this study, E.	coli were 
the major isolates collected from HTAA, and also 




E.coli K.  pneumoniae
n	(%)
β-lactams S I R S I R
Ampicillin 44 (29.5) 1 (0.7) 104 (69.8) 3 (2.7) 2 (1.8) 105 (95.5)
Amoxicillin/
Clavulanic	Acid
104 (69.8) 21 (14.1) 24 (16.1) 67 (60.9) 9 (8.2) 34 (30.9)
Piperacillin 86 (57.7) 2 (1.3) 61 (41.0) 50 (45.5) 12 (10.9) 48 (43.6)
Piperacillin/
Tazobactam
134 (90.0) 2 (1.3) 13 (8.7) 76 (69.1) 5 (4.5) 29 (26.4)
Sulbactam/
Ampicillin
106 (71.1) 8 (5.4) 35 (23.5) 72 (65.5) 2 (1.8) 36 (32.7)
Cefotaxime 116 (77.9) 0 (0.0) 33 (22.1) 70 (63.6) 1 (0.9) 39 (35.5)
Ceftazidime 126 (84.6) 0 (0.0) 23 (15.4) 71 (64.5) 1 (1.0) 38 (34.5)
Cefepime 128 (85.9) 5 (3.4) 16 (10.7) 77 (70.0) 2 (1.8) 31(28.2)
Cefuroxime 114 (76.5) 1 (0.7) 34 (22.8) 67 (60.9) 4 (3.6) 39 (35.5)
Meropenem 149 (100) 0 (0.0) 0 (0.0) 106 (96.4) 0 (0.0) 4 (3.6)
Imipenem 149 (100) 0 (0.0) 0 (0.0) 106 (96.4) 0 (0.0) 4 (3.6)
Ertapenem 148 (99.3) 0 (0.0) 1 (0.7) 105 (95.5) 0 (0.0) 5 (4.5)
Non β-lactams S I R S I R
Amikacin 149 (100) 0 (0.0) 0 (0.0) 106 (96.4) 0 (0.0) 4 (3.6)
Ciprofloxacin 123 (82.5) 4 (2.7) 22 (14.8) 78 (70.9) 10 (9.1) 22 (20.0)
Gentamicin 131 (87.9) 0 (0.0) 18 (12.1) 81 (73.6) 1 (0.9) 28 (25.5)
Chloramphenicol 122 (81.9) 1 (0.7) 26 (17.4) 86 (78.2) 0 (0.0) 24 (21.8)
polymyxin	B 144 (96.6) 0 (0.0) 5 (3.4) 95 (86.4) 0 (0.0) 15 (13.6)
Trimethoprim-
Sulfamethoxazole
79 (53.0) 1(0.7) 69 (46.3) 66 (60.0) 2 (1.8) 42 (38.2)




























K.	pneumoniae 32 (29.0) 28 (87.5) 17 (53.1) 16 (50.0) 16 (50.0) 14 (43.8) 8 (25.0)
E.coli 18 (12.0) 17 (94.4) 9 (50.0) 12 (66.7) 9 (50.0) 11 (61.1) 6 (33.3)
Total 50 (19.3) 45 (90.0) 26 (52.0) 28 (56.0) 25 (50.0) 25 (50.0) 14 (28.0)
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the most common aetiological agent for urinary 
tract infection. However, the frequency of ESBL-
production by K.	 pneumoniae (35.5%; 39/110) 
was higher than that by E.	coli (18.8%; 28/149). 
Most of the ESBL-producing K.	 pneumoniae 
were also derived from urine specimens. The 
high occurrence of ESBL among K.	pneumoniae 
is perhaps due to the nature of its nosocomial 
presence and the survival of diverse replicons 
carried by the multidrug-resistant K.	pneumoniae 
isolates (16). The mechanism of drug resistance 
has been associated with several chromosomal 
and plasmid-encoded genes (1,3). The ESBL 
prevalence shown in this study was relatively 
similar when compared to that reported in the 
National Surveillance of Antibiotic Resistance 
(NSAR) report for 2014 (17), which was lower 
than that documented in India, China, Thailand 
and Pakistan, in which the prevalence of ESBLs 
ranged between 47% and 70% for K.	pneumoniae 
and 37% and 67% for E.	coli (2)(18,19). 
 Since the past decade CTX-M-positive K.	
pneumoniae and E.	 coli have been reported as 
significant and the most prevalent ESBL producers 
throughout the world and particularly in several 
Asian countries (2) (18,19). In the present study, 
blaCTX-M was the dominant gene detected among 
90% of the total ESBL-positive isolates (Table 
3). This finding is consistent with the known 
geographic distribution of CTX-M-type ESBL in 
the Asia-Pacific region, 97% in China, 95.4% in 
India, 93.1% in Malaysia, 87.1% in Singapore, 
and 85.4% in South Korea (16,19–21). The CTM-
M-positive strain is not only found in a clinical 
setting but is also dominant among Klebsiella	
sp. and Escherichia	sp. in the environment, such 
as on the urban water surface in Malaysia (22). 
Transmission of resistant organisms between 
environments is possible (1). The high rates of 
CTX-M β-lactamase production might be due to 
the high selective pressure imposed by widely 
used cephalosporins, particularly cefotaxime and 
ceftriaxone. 
 Our finding was consistent with other reports 
on ESBL genotype prevalence from Malaysian 
hospitals (16,23); however, it was in contrast to the 
previous report by Lim et al., (24) whereby they 
found that the blaSHV gene was the predominant 
ESBL genotype among K.	 pneumoniae isolates. 
Changes in distribution of ESBL genes may vary, 
as differences in genotype prevalence have been 
noted not only between different countries but 
even between different institutions in the same 
region (18). 
 The high rates of ESBL-positive strains of K.	
pneumoniae and E.	coli were also associated with 
the presence of blaSHV (56%) and blaTEM (52%) genes 
(Table 3). This is in line with a study conducted 
in an Indian tertiary hospital, which revealed 
that blaSHV and blaTEM genes were detected among 
60% and 56% of the above ESBL-positive isolates, 
respectively (25). Several ESBL-positive strains 
were detected carrying more than one ESBL-
encoding gene. Three categories of isolates were 
noted; the first carried only one ESBL-encoding 
gene, the second carried two different genes and 
the third harboured three ESBL-encoding genes as 
summarised in Table 3. The presence of two ESBL 
gene types, blaCTX-M + blaSHV or blaCTX-M + blaTEM 
combination, was found among 50% of the total 
ESBL-positive isolates. The presence of a three-
ESBL-gene combination in the same strain was 
found in 28% (14/50) of the total ESBL-positive 
strains. Similar findings were reported in a study 
conducted in Thailand (26). These enzymes are 
plasmid-encoded β-lactamases, which can be 
easily transferred among isolates and between 
species in nature. Further study on the plasmids 
characteristic of isolates carrying multiple bla 
genes would be worthwhile to understand their 
mechanism of resistance and dissemination. 
Conclusion
 In conclusion, several antimicrobial agents 
recommended for treatment of K.	 pneumoniae 
and E.	 coli infections were found to be effective 
in-vitro. Approximate prevalence and molecular 
characterisation of ESBL-producing K.	
pneumoniae and E.	 coli isolates from HTAA 
demonstrated a high rate of CTX-M-positive 
strains. The same strains may also harbour 
multiple ESBL genes. The significant proportion 
rate of these resistant determinants is alarming. 
Thus, early and regular surveillance of these 
determinants and their genotypic characterization 
is essential for monitoring their transmission and 
dissemination in order to halt it or control it at an 
early phase. 
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